Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.

Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG.

Cancer Res. 2011 Mar 15;71(6):2360-70. doi: 10.1158/0008-5472.CAN-10-1933.

2.

EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.

Li T, Cai J, Ding H, Xu L, Yang Q, Wang Z.

Cancer Biol Ther. 2014 Mar 1;15(3):271-8. doi: 10.4161/cbt.27306. Epub 2013 Dec 12.

3.

Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.

Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG.

Oncogene. 2009 Feb 12;28(6):843-53. doi: 10.1038/onc.2008.433. Epub 2008 Dec 15.

4.

Phosphatidylinositol 3-kinase/Akt signaling enhances nuclear localization and transcriptional activity of BRCA1.

Hinton CV, Fitzgerald LD, Thompson ME.

Exp Cell Res. 2007 May 15;313(9):1735-44. Epub 2007 Mar 15.

5.
6.
7.

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM.

Breast Cancer Res. 2009;11(4):R63. doi: 10.1186/bcr2354. Epub 2009 Aug 26.

8.

Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3.

Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP, Hung MC.

Science. 2005 Oct 14;310(5746):306-10.

9.
10.

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.

11.

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.

Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.

12.

JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic.

Chen B, Liu J, Chang Q, Beezhold K, Lu Y, Chen F.

Cell Cycle. 2013 Jan 1;12(1):112-21. doi: 10.4161/cc.23030. Epub 2012 Dec 19.

13.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K.

Mol Cancer Ther. 2006 Dec;5(12):3096-104.

14.

MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.

Fujii S, Tokita K, Wada N, Ito K, Yamauchi C, Ito Y, Ochiai A.

Oncogene. 2011 Sep 29;30(39):4118-28. doi: 10.1038/onc.2011.118. Epub 2011 Apr 18.

PMID:
21499305
15.

Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.

Huang W, Gonzalez ME, Toy KA, Banerjee M, Kleer CG.

Cancer Res. 2010 Apr 15;70(8):3340-50. doi: 10.1158/0008-5472.CAN-09-4225.

18.

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.

Oncol Rep. 2012 Jun;27(6):1703-9. doi: 10.3892/or.2012.1724. Epub 2012 Mar 15.

PMID:
22426819
19.

Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, Palmieri E, Pezzullo L, Palombini L, Fusco A, Viglietto G.

Am J Pathol. 2005 Mar;166(3):737-49.

20.

EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG.

Breast Cancer Res Treat. 2013 Apr;138(3):741-52. doi: 10.1007/s10549-013-2498-x. Epub 2013 Mar 29.

Supplemental Content

Support Center